Facing a Tirzepatide Shortage? Here Is What to Do Next

Is there actually a shortage, or is your pharmacy just out of stock?

The distinction matters. A national shortage is formally notified through DHSC supply channels and typically means all wholesalers are affected for a period. A single pharmacy showing a dose as unavailable is far more common, and far less serious. It may mean that specific pharmacy has sold through its allocation, or that the dose you need is on short lead time locally.

Before drawing conclusions, it is worth checking whether another registered pharmacy has your dose in stock, or whether your prescriber can confirm that a national notification is in place. Our dedicated page on the current Mounjaro shortage picture pulls together what is actually known about supply, updated as the situation changes.

The MHRA and DHSC publish medicine supply notifications publicly. If no notification is active for your dose, the problem is likely local and often resolves within days. If a notification is in place, the decisions below become more relevant.

What your prescriber can actually do during a shortage

This is where most people get stuck: they know supply is disrupted, but they are unsure whether to pause, switch dose, or wait. The answer depends on your clinical picture, which is exactly why this is a prescriber decision, not a patient one.

Clinically, a prescriber might consider holding your current dose at a lower available strength rather than titrating up as planned, bridging on the nearest available pen until supply resumes, or in some cases discussing whether a licensed alternative is appropriate. None of those paths is right or wrong in the abstract; they depend on how long you have been on treatment, how your body is responding, and what your other health considerations are.

If you are a new patient who started tirzepatide through a private clinic and your original provider cannot source your dose, a regulated pharmacy with its own prescribing team can carry out a clinical review and take over your care, provided you can supply evidence of your current treatment and most recent weight. Our clinical team handles transfer consultations as a matter of routine.

For broader context on how shortage patterns have developed over time, the Mounjaro shortage history in the UK covers the timeline in detail.

The counterfeit risk is highest when supply is tight

It is entirely understandable to feel frustrated. You have started to see results, you have built a routine around weekly injections, and now you are being told the pen you need is unavailable. That frustration is real, and it makes the lure of a seller on social media or a suspiciously cheap listing seem more tempting than it would otherwise be.

The MHRA has been explicit on this: enforcement operations through 2025 seized large quantities of fake weight-loss pens and shut down the first illicit UK manufacturing site producing counterfeit tirzepatide, in Northampton. Fake pens have in some cases contained insulin rather than tirzepatide, a potentially dangerous substitution. The rule is straightforward: only source tirzepatide from a pharmacy you can verify on the GPhC register at pharmacyregulation.org. If a seller is offering it without a clinical assessment or at prices far below anything you have seen from a registered provider, that is a red flag, not a deal.

Suspect sellers can be reported directly through the MHRA Yellow Card scheme, which also covers suspected side effects.

What to consider if shortage is ongoing and your decision is larger

If the shortage affecting your dose is expected to last weeks rather than days, you face a more considered decision: wait it out, switch to an available strength, or explore whether a different licensed weight-management medicine is clinically suitable for you.

Context on tirzepatide treatment costs is worth reading if you are assessing private options afresh, understanding what a full-service price includes (consultation, prescription, delivery, aftercare) helps you compare providers on the right basis, not just headline figures.

Some patients also ask whether the shortage signals that they should look at tirzepatide's clinical profile more broadly before committing further. Our tirzepatide overview covers the evidence base, the licensed dose schedule, and eligibility criteria in full. For a closer look at Mounjaro specifically as the branded product available in the UK, the Mounjaro guide is a useful starting point. And if you want a live read on where supply stands today rather than the broader picture, the Mounjaro shortage update page is updated as new information becomes available.

The one decision we would caution against is doing nothing at all, neither sourcing medicine safely nor speaking to your prescriber. Stopping tirzepatide without guidance can lead to appetite returning faster than expected, and restarting after a gap usually means returning to a lower dose to let your body readjust. A brief conversation with a prescriber costs nothing in that equation and could save you weeks of unnecessary regression. If you would like that conversation now, our prescribers are available seven days a week, start a free consultation and a GPhC-registered clinician will review your situation the same day.